Mikael Søndergaard Thomsen

Novartis Pharma Schweiz AG engages in the marketing and distribution of pharmaceutical, chemical, and medical products of the Novartis group. Its products are used in the treatment of diseases in the areas of neurology, immunology, dermatology, ophthalmology, cardiology, and oncology. The company was founded on December 10, 1986 and is headquartered in Rotkreuz, Switzerland.

Oxford UK Ltd is a private company based in Brighouse, UK. and has subsidiaries in the United Kingdom. The British company was founded by Mikael Søndergaard Thomsen.

Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK

US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD.

Bridge Bioresearch Plc develops drug for obesity and metabolic disorders. It is a drug development company focusing on general phase 2a clinical trials as well as acquisition of novel drugs for treatment of widespread metabolic disorders, within the field of life style induced diseases such as Obesity, Type 2 Diabetes and Hypertension. The company is headquartered in London, the United Kingdom.

Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ.

Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.